FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel- results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

DSpace Repositorium (Manakin basiert)

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel- results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

Autor(en): Lorenzen, Sylvie; Thuss-Patience, Peter; Pauligk, Claudia; Goekkurt, Eray; Ettrich, Thomas; Lordick, Florian; Stahl, Michael; Reichardt, Peter; Soekler, Martin; Pink, Daniel; Probst, Stefan; Hinke, Axel; Goetze, Thorsten O.; Al-Batran, Salah E.
Tübinger Autor(en):
Sökler, Martin
Erschienen in: European Journal of Cancer (2022), Bd. 165, S. 48-57
Verlagsangabe: Elsevier Sci Ltd
Sprache: Englisch
Referenz zum Volltext: http://dx.doi.org/10.1016/j.ejca.2022.01.015
ISSN: 0959-8049
DDC-Klassifikation: 610 - Medizin, Gesundheit
Dokumentart: Wissenschaftlicher Artikel
Zur Langanzeige

Das Dokument erscheint in: